Skip to main content
RYAN
NYSE Finance

Ryan Specialty Q3 Revenue Up 4.7% but Organic Growth Slows to 4.0%; Guidance Trimmed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Insurance Stocks · Financial
Sentiment info
Negative
Importance info
8
Price
$43.28
Mkt Cap
$11.072B
52W Low
$29.28
52W High
$58.94
52W Position info
48% above low
Off High info
27% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

RYAN sits 48% above its 52-week low of $29.28.

Summary

Ryan Specialty's Q3 organic revenue growth fell to 4.0% from 15.0% a year ago, even as revenue rose 4.7% to $790.0M and adjusted diluted EPS climbed 8.5% to $0.51. The company held its mid-single-digit organic growth guide but now expects Adjusted EBITDAC margin down modestly for 2026.


Key Events · Earnings and Guidance · RYAN

  • Organic Growth Slows to 4.0%

    Organic revenue growth decelerated to 4.0% in Q3 2026 from 15.0% a year ago — the sharpest slowdown in recent quarters — on total revenue of $790.0M (+4.7%).

  • Margins Slip, EPS Still Grows

    Adjusted EBITDAC rose 3.8% to $244.4M but margin fell to 30.9% from 31.2%; adjusted diluted EPS rose 8.5% to $0.51 and net income jumped 40.6% to $88.0M.

  • Guidance: Margin Now Down Modestly

    Full-year 2026 organic revenue growth is guided to mid-single digits, with Adjusted EBITDAC margin now expected down modestly versus the prior year.

  • Capital Return Continues

    The company returned $173.7M in Q3 via $150.0M of buybacks (3.5M shares) and $23.7M of dividends/distributions; $150.0M remains on the repurchase authorization.


Analysis · RYAN · Finance

The headline is the organic growth collapse to 4.0% from 15.0% a year ago — the sharpest deceleration in recent memory for a company that has traded on premium growth multiples. Revenue of $790.0M (+4.7%) and adjusted EBITDAC of $244.4M (+3.8%) still grew, and adjusted diluted EPS rose 8.5% to $0.51, but the margin slipped to 30.9% from 31.2%. Management kept its mid-single-digit organic growth target for 2026 while now guiding Adjusted EBITDAC margin down modestly versus last year — a soft profit outlook layered on a growth slowdown. The $150.0M buyback authorization remaining and a $0.13 quarterly dividend show capital return continues, but they do not offset the growth reset.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RYAN was trading at $43.28 on NYSE in the Finance sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $29.28 to $58.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RYAN - Latest Insights

RYAN
Oct 30, 2026, 7:32 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $42.30
Real-time Price: $46.88 info
Change: +$4.58 (+11%) info
Market Cap: $11.61B info
RYAN
Oct 29, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $43.28
Real-time Price: $46.88 info
Change: +$3.60 (+8%) info
Market Cap: $11.61B info
RYAN
Jul 31, 2026, 7:32 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.25
Real-time Price: $46.88 info
Change: -$2.37 (-5%) info
Market Cap: $11.61B info
RYAN
Jul 30, 2026, 4:31 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $49.50
Real-time Price: $46.88 info
Change: -$2.62 (-5%) info
Market Cap: $11.61B info
RYAN
Jul 30, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.50
Real-time Price: $46.88 info
Change: -$2.62 (-5%) info
Market Cap: $11.61B info